Home › Research › Biomarkers
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T et al.. JAMA, 2024-10-01
Topic: Amyloid, tau and blood-test diagnosis
Results The mean age was 74.2 years (SD, 8.3 years), 48% were women, 23% had subjective cognitive decline, 44% had mild cognitive impairment, and 33% had dementia. In the overall population, the diagnostic accuracy using the APS2 (90% [95% CI, 88%-92%]) was not different from the diagnostic accuracy using the percentage of p-tau217 alone (90% [95% CI, 88%-91%]).
Key findings
- Results The mean age was 74.2 years (SD, 8.3 years), 48% were women, 23% had subjective cognitive decline, 44% had mild cognitive impairment, and 33% had dementia.
- In the overall population, the diagnostic accuracy using the APS2 (90% [95% CI, 88%-92%]) was not different from the diagnostic accuracy using the percentage of p-tau217 alone (90% [95% CI, 88%-91%]).
Why it matters
In a group of older adults ranging from subjective cognitive decline to dementia, a blood test detected Alzheimer's disease with 90% diagnostic accuracy. The percentage of p-tau217 on its own did no worse than the combined APS2 score, which suggests a single blood marker could help detect Alzheimer's in primary and secondary care.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants307
- Evidence strengthModerate
How this study scored 72/100
Published in a top-tier journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 307 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 395 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 98.8 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 6 / 6 | Cited 107.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 54 other studies in this library |
| Still being cited | 4 / 4 | Cited 394 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39068545) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., et al. (2024). Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. https://doi.org/10.1001/jama.2024.13855
Vancouver
Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. 2024. doi:10.1001/jama.2024.13855. PMID: 39068545.
BibTeX
@article{palmqvist2024-39068545,
author = {Palmqvist, S. and Tideman, P. and Mattsson-Carlgren, N. and Schindler, S. E. and Smith, R. and Ossenkoppele, R. and Calling, S. and West, T. and others},
title = {{Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care}},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.13855},
pmid = {39068545},
url = {https://doi.org/10.1001/jama.2024.13855}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.
Later studies that cite this one
54 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.